Optimizing Medi-Cal Biologics Prior Auth Workflows

Navigating Medi-Cal biologics prior auth can be complex, but Klivira streamlines the entire submission process for high-cost specialty drugs, ensuring compliance and efficiency.

For revenue cycle directors and prior authorization coordinators managing specialty drug approvals, the unique requirements of Medi-Cal for biologics present significant operational challenges. These high-cost therapies, critical for conditions in rheumatology, gastroenterology, and dermatology, demand precise documentation and adherence to specific step therapy protocols. Klivira provides a robust solution designed to automate and accelerate this critical workflow.

The Operational Burden of Medi-Cal Biologics Prior Auth

Biologics, including TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, represent a substantial segment of high-cost specialty drug prior authorizations. For California's Medicaid program, Medi-Cal, these approvals involve complex, indication-specific criteria and often require extensive documentation of prior-line therapies and screening results. The volume and specificity of these requirements can strain existing PA teams, impacting patient access and revenue cycles.

Klivira's Automated Biologics PA Workflow for Medi-Cal

Klivira's platform automates the critical steps involved in securing Medi-Cal biologics prior auth. By integrating directly with EMRs, our system intelligently gathers required clinical data, applies payer-specific logic, and prepares submissions tailored to Medi-Cal's documentation needs, regardless of the submission channel (X12 278, ePA, or portal). This approach significantly reduces manual data entry and accelerates approval cycles for specialty biologics.

Streamlined Biologics PA Through Intelligent Automation

Indication Classification: Automatically identifies specialty and disease state from EMR diagnoses, ensuring accurate application of Medi-Cal's indication-specific criteria.
Step Therapy Automation: Pulls prior-line therapy history (e.g., csDMARDs for rheumatology) from structured and unstructured EMR data to fulfill Medi-Cal's step therapy requirements.
Biosimilar Substitution Routing: Applies per-payer biosimilar mandates, guiding submissions to align with Medi-Cal's preferred biosimilar pathways where applicable.
Screening Documentation: Extracts and attaches necessary screening results, such as TB, hepatitis B/C, and immunization status, directly from FHIR-enabled EMRs.
Periodic Re-authorization: Manages ongoing 6- or 12-month re-authorization cycles, ensuring continuous documentation of disease activity and treatment response.
Medical vs. Pharmacy Benefit Routing: Differentiates between medical and pharmacy benefit pathways for the same agent based on administration mode, ensuring correct submission to Medi-Cal.

Navigating Medi-Cal's Specific Requirements

While specific submission channels for Medi-Cal biologics prior auth can vary, Klivira's platform is engineered to adapt. Our system supports various electronic and manual submission pathways, ensuring that all required clinical attachments and forms are accurately completed and transmitted. This includes managing the nuances of documentation for drug classes like TNF inhibitors and IL-23 inhibitors, helping to mitigate common rejection factors.

Enhancing Operational Efficiency and Patient Access

Automating Medi-Cal biologics prior auth workflows with Klivira translates directly into tangible benefits for health systems. By reducing the administrative burden, PA coordinators can focus on complex cases, improving overall team productivity. This efficiency also accelerates approval times, ensuring patients receive critical biologic therapies without unnecessary delays, a key factor in managing chronic conditions across specialties.

Frequently asked questions

How does Klivira handle specific Medi-Cal documentation requirements for biologics?

Klivira's platform is configured to identify and extract the precise clinical data points required for Medi-Cal biologics prior authorizations directly from your EMR. This includes indication-specific criteria, prior-line therapy history, and screening results, ensuring all necessary documentation is compiled and formatted correctly for submission.

Can Klivira integrate with our EMR to pull data for Medi-Cal biologics PA?

Yes, Klivira integrates seamlessly with major EMR systems using standards like SMART on FHIR. This integration allows for automated extraction of patient demographics, diagnoses, medication history, lab results, and other clinical notes essential for completing Medi-Cal biologics prior auth requests, minimizing manual data entry.

Does Klivira address step therapy requirements for Medi-Cal biologics?

Absolutely. Klivira's intelligent workflow incorporates Medi-Cal's specific step therapy protocols for biologics. The system automatically identifies and documents prior-line therapies from the EMR, such as csDMARDs for rheumatology or 5-ASA for IBD, ensuring compliance with payer guidelines before submission.

How does Klivira support biosimilar substitution policies for Medi-Cal?

Klivira's platform incorporates payer-specific biosimilar substitution policies. For Medi-Cal biologics prior auth, the system guides the PA process to align with any mandated biosimilar first-try requirements, helping to ensure submissions are compliant and reduce potential denials related to preferred agent selection.

What about periodic re-authorization for chronic biologic treatments with Medi-Cal?

Klivira automates the management of periodic re-authorization for chronic biologic treatments. The system tracks typical 6- or 12-month cycles and prompts for the necessary continuous disease-activity and response documentation required by Medi-Cal for ongoing approval, streamlining a common source of administrative burden.